Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report.
J Int Assoc Provid AIDS Care
; 12(5): 312-4, 2013.
Article
en En
| MEDLINE
| ID: mdl-23695227
The use of raltegravir (RAL) is not preferred to prevent perinatal transmission in pregnancy due to lack of safety and pharmacokinetic data in this population. Data have been limited to few case reports of patients who present for treatment late in pregnancy, have multidrug resistance, or have poor adherence, requiring an additional class such as an integrase inhibitor to further lower viral load. This case report describes and supports the initiation of RAL in very late pregnancy (week 33) to rapidly decrease viral load and successfully prevent perinatal transmission. By increasing the efficacy and safety data of RAL use in pregnancy, we believe this report can help provide some guidance on the management of complex cases.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
Problema de salud:
1_doencas_nao_transmissiveis
/
2_enfermedades_transmissibles
Asunto principal:
Complicaciones Infecciosas del Embarazo
/
Pirrolidinonas
/
Infecciones por VIH
/
Transmisión Vertical de Enfermedad Infecciosa
/
Fármacos Anti-VIH
Tipo de estudio:
Guideline
Límite:
Adult
/
Female
/
Humans
/
Newborn
/
Pregnancy
Idioma:
En
Revista:
J Int Assoc Provid AIDS Care
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos